Viatris Inc.
NASDAQ:VTRSDrug Manufacturers - Specialty & Generic
-$0.36 today
- Market cap
- $23.25B
- Beta
- 0.90
- P/E (TTM)
- -59.9
- EPS (TTM)
- -$0.26
- Dividend yield
- 3.12%
Volume 13.21M
Average 10.58M
VTRS Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Viatris Inc.NASDAQ: VTRS
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures dips below year-ago levels
Q2 FY2026 capital expenditures of $52.8M (cash outflow) fell 2.4% year over year, behind the +23.9% change in trailing-twelve-month capital expenditures. Sequentially, it rose 32.3% from the prior quarter. Over 3 fiscal years it compounded at -8.2% a year.
Context
- Capital expenditures amounted to 2.6% of revenue in FY2025, up 0.4 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -2.4% toward the trailing-twelve-month pace of +23.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (378.8M) USD
- Year-over-year change
- -16.2%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (378.8M) | -16.2% |
| FY2024 | 2024-12-31 | (326M) | +31.3% |
| FY2023 | 2023-12-31 | (474.5M) | +3.0% |
| FY2022 | 2022-12-31 | (489.4M) | +3.9% |
| FY2021 | 2021-12-31 | (509.4M) | — |
Capital Expenditures vs competitors
How VTRS compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +23.9% is the 4th highest of 10, against a peer median of +1.8%.
- Capital expenditures amounts to 3.1% of revenue for VTRS, versus a peer median of 3.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | ₹18.1B INR | -55.1% | +9.2% | 5.5% | |
| LTM Jun 2026 | $550M USD | +10.0% | -2.9% | 3.2% | |
| LTM Jun 2026 | $457.7M USD | +23.9% | -8.2% | 3.1% | |
| LTM Jun 2026 | $408.39M USD | +1.8% | +14.0% | 3.8% | |
| FY2025 | £314.94M GBP | +26.0% | -1.3% | 2.9% | |
| LTM Sep 2026 | $168M USD | -56.1% | -27.6% | 2.8% | |
| LTM Jun 2026 | $117.67M USD | +32.8% | -8.2% | 3.8% | |
| LTM Mar 2026 | $48.26M USD | +52.8% | +27.8% | 5.2% | |
| LTM Mar 2026 | $33.69M USD | -21.5% | +13.2% | 4.7% | |
| LTM Sep 2026 | $15.62M USD | -68.9% | +1.9% | 0.9% | |
| Peer median (excluding VTRS) | — | +1.8% | +1.9% | 3.8% | |
Competitors are the stored peer set for VTRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.27B) | 2.08B | 54.7M | (634.2M) | (3.51B) |
| Depreciation & Amortization | 4.51B | 3.03B | 2.74B | 2.71B | 2.8B |
| Deferred Income Tax | 675.7M | (25.9M) | (387.1M) | (767.6M) | (476.5M) |
| Stock-Based Compensation | 111.2M | 116.4M | 180.7M | 146.1M | 177.7M |
| Change in Working Capital | (1.8B) | (922.6M) | (711.3M) | (318.6M) | (2.5B) |
| Accounts Receivables | 59.3M | (240.3M) | 78.6M | 300.1M | 334.6M |
| Inventory | (427.6M) | (259.5M) | (613.3M) | (723.4M) | (106.4M) |
| Accounts Payables | (70.4M) | 170.2M | 314.7M | 36M | (168M) |
| Other Working Capital | (1.37B) | (593M) | (491.3M) | 68.7M | (2.56B) |
| Other Non-Cash Items | 797.4M | (1.28B) | 922.1M | 1.17B | 5.84B |
| Operating Cash Flow | 3.02B | 3B | 2.8B | 2.3B | 2.32B |
| Capital Expenditures | (509.4M) | (489.4M) | (474.5M) | (326M) | (378.8M) |
| Acquisitions (Net) | 277M | 0 | (667.7M) | (350M) | 0 |
| Purchases of Investments | (30.2M) | (30.2M) | (26.3M) | (26M) | (23.9M) |
| Sales of Investments | 29.8M | 29.9M | 26.3M | 26M | 23.9M |
| Other Investing Activities | 115M | 1.96B | 280.6M | 2.48B | (48.9M) |
| Investing Cash Flow | (117.8M) | 1.47B | (764.1M) | 1.8B | (427.7M) |
| Debt Repayment | (2.1B) | (3.28B) | (1.25B) | (3.71B) | 100K |
| Common Stock Issued | 0 | 3.3M | 3.1M | 2.5M | 2.6M |
| Common Stock Repurchased | (17.4M) | 0 | (250M) | (250M) | (500.5M) |
| Dividends Paid | (399M) | (581.6M) | (575.6M) | (574.8M) | (561.2M) |
| Other Financing Activities | (496.5M) | (19.5M) | (229.8M) | 205.6M | (234.9M) |
| Financing Cash Flow | (3.01B) | (3.88B) | (2.3B) | (4.33B) | (1.29B) |
| Effect of Forex Changes | (30.9M) | (38.9M) | (2.5M) | (30.7M) | 17.6M |
| Net Change in Cash | (143.8M) | 556.3M | (268.9M) | (257.5M) | 611.9M |
| Free Cash Flow | 2.51B | 2.51B | 2.33B | 1.98B | 1.94B |
Viatris Inc.
NASDAQ:VTRS
Intrinsic Alpha fair value
Locked
Current Price
$20.28
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.